{"id":"masitinib-4-5","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Rash"},{"rate":null,"effect":"Edema"},{"rate":null,"effect":"Abdominal pain"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Masitinib inhibits multiple tyrosine kinases involved in mast cell and immune cell activation, particularly c-KIT and PDGFR. By blocking these kinases, it reduces mast cell degranulation and inflammatory mediator release, thereby modulating immune responses in conditions characterized by excessive mast cell activation or pathological inflammation.","oneSentence":"Masitinib is a tyrosine kinase inhibitor that selectively targets c-KIT, PDGFR, and Lyn kinases to modulate immune cell function and reduce pathological inflammation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:20:10.158Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Gastrointestinal stromal tumor (GIST)"},{"name":"Amyotrophic lateral sclerosis (ALS)"},{"name":"Pancreatic cancer"},{"name":"Mastocytosis"}]},"trialDetails":[{"nctId":"NCT05564169","phase":"PHASE3","title":"Masitinib in Patients With Mild Alzheimer's Disease","status":"NOT_YET_RECRUITING","sponsor":"AB Science","startDate":"2026-06","conditions":"Alzheimer Disease","enrollment":600},{"nctId":"NCT07174492","phase":"PHASE3","title":"Efficacy and Safety of Masitinib in Combination With SoC Versus Placebo in the Treatment of ALS Patients","status":"NOT_YET_RECRUITING","sponsor":"AB Science","startDate":"2026-01-01","conditions":"Amyotrophic Lateral Sclerosis (ALS)","enrollment":412},{"nctId":"NCT03127267","phase":"PHASE3","title":"Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS Patients","status":"RECRUITING","sponsor":"AB Science","startDate":"2021-02-02","conditions":"Amyotrophic Lateral Sclerosis","enrollment":495},{"nctId":"NCT05441488","phase":"PHASE3","title":"Masitinib in the Treatment of Patients With Primary Progressive or Non-active Secondary Progressive Multiple Sclerosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"AB Science","startDate":"2022-06-28","conditions":"Progressive Multiple Sclerosis","enrollment":800},{"nctId":"NCT02588677","phase":"PHASE2, PHASE3","title":"Masitinib in Combination With Riluzole for the Treatment of Patients Suffering From Amyotrophic Lateral Sclerosis (ALS)","status":"COMPLETED","sponsor":"AB Science","startDate":"2013-04","conditions":"Amyotrophic Lateral Sclerosis (ALS)","enrollment":394},{"nctId":"NCT01872598","phase":"PHASE3","title":"Masitinib in Patients With Mild to Moderate Alzheimer's Disease","status":"COMPLETED","sponsor":"AB Science","startDate":"2012-01","conditions":"Alzheimer Disease","enrollment":721},{"nctId":"NCT04333108","phase":"PHASE3","title":"Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis Unresponsive to Optimal Symptomatic Treatment","status":"UNKNOWN","sponsor":"AB Science","startDate":"2020-07-01","conditions":"Indolent Systemic Mastocytosis","enrollment":140},{"nctId":"NCT05047783","phase":"PHASE2","title":"Masitinib in Patients With Symptomatic Mild to Moderate COVID-19","status":"UNKNOWN","sponsor":"AB Science","startDate":"2021-11-23","conditions":"Covid19, SARS-CoV2 Infection, Coronavirus Disease 2019","enrollment":78},{"nctId":"NCT04622865","phase":"PHASE2","title":"Masitinib Combined With Isoquercetin and Best Supportive Care in Hospitalized Patients With Moderate and Severe COVID-19","status":"UNKNOWN","sponsor":"AB Science","startDate":"2020-06-01","conditions":"SARS-CoV 2, COVID-19, Coronavirus Disease 2019","enrollment":200},{"nctId":"NCT05449444","phase":"PHASE2","title":"Masitinib for the Treatment of Severe Mast Cell Activation Syndrome","status":"UNKNOWN","sponsor":"AB Science","startDate":"2022-07-01","conditions":"Mast Cell Activation Syndrome","enrollment":72},{"nctId":"NCT03771040","phase":"PHASE3","title":"Masitinib in the Treatment of Patients With Severe Uncontrolled Asthma and Elevated Eosinophil Levels","status":"COMPLETED","sponsor":"AB Science","startDate":"2016-12","conditions":"Asthma","enrollment":347},{"nctId":"NCT01433497","phase":"PHASE3","title":"Efficacy and Safety of Masitinib in the Treatment of Progressive Multiple Sclerosis","status":"COMPLETED","sponsor":"AB Science","startDate":"2011-08","conditions":"Multiple Sclerosis, Secondary Progressive, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Relapse Free","enrollment":656}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["AB1010"],"phase":"phase_3","status":"active","brandName":"Masitinib (4.5)","genericName":"Masitinib (4.5)","companyName":"AB Science","companyId":"ab-science","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Masitinib is a small molecule inhibitor of the fibroblast growth factor receptor 3. It is being studied in clinical trials for conditions such as Alzheimer's disease, amyotrophic lateral sclerosis (ALS), and mast cell activation syndrome.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}